samedan logo

 
 
spacer
home > white papers > Accelerating the Time from DNA to Material - Merck
WHITE PAPERS
logo_Merck.jpg

Merck

phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web http://www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Accelerating the Time from DNA to Material

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
Accelerating the Time from DNA to Material
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >>


White Papers

Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement